Asian Investment Conference 2021
CEO, Insilico Medicine
Alex Zhavoronkov is CEO of Insilico Medicine. Insilico Medicine is a leader in next-generation artificial intelligence (AI) technologies for drug discovery and biomarker development. He is also Founder and CEO of Deep Longevity, Incorporated, a global company developing a broad range of AI-based biomarkers of aging and longevity.
Since 2015, Dr. Zhavoronkov has been inventing critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel molecular structures with desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer of learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico has raised over $50 million in multiple rounds from expert investors, opened research and development centres in six countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions.
Prior to founding Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, and Biogerontology Research Foundation. Since 2012, he has published over 130 peer-reviewed research papers, and two books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe's largest industry events in drug discovery. He is the adjunct professor for AI at the Buck Institute for Research on Aging.